Ferring’s key product PENTASA® is used for the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Ferring offers many different dosage-forms for PENTASA such as tablets, sachets, suppositories and rectal suspensions and is currently developing further-improved formulations.

New PENTASA formulations
Ferring has developed a 2-gram sachet to facilitate medication intake for patients who require higher doses. Ferring is also investigating changes to the enema presentation using a new device to facilitate rectal administration.

Gastroenterology Products in Early Development
Ferring Pharmaceuticals and Conaris Research Institute AG announced in December 2008 that they have completed an exclusive worldwide license agreement for the development of FE301 a new recombinant protein inhibitor of the IL-6 pathway for inflammatory conditions such as IBD and rheumatoid arthritis. See press release.